Skip to content

Effect of local infiltration using ropivacaine combined with celebrex and pregabalin on the pain control of spinal surgery

Effect of local infiltration using ropivacaine combined with celebrex and pregabalin on the pain control of spinal surgery: randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031236
Enrollment
Unknown
Registered
2020-03-25
Start date
2020-03-25
Completion date
Unknown
Last updated
2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain management of spinal surgery

Interventions

Group 1:Local subcutaneous infiltration at 0.75% ropivacaine suture, 2h preoperative celebrex (400 mg), prerabalin (150 mg), then daily celebrex (200 mg, bid), prerabalin (75 mg, bid)
Group 2:Local subcutaneous infiltration was observed with 0.75% ropivacaine suture

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-90 years; 2. Single segment fusion internal fixation: lumbar disc herniation, lumbar spinal stenosis, lumbar spondylolisthesis; 3. Double segment fusion internal fixation: lumbar disc herniation, lumbar spinal stenosis, lumbar spondylolisthesis; 4. Internal fixation of thoracolumbar fractures.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to local amines or sulfanilamide; 2. Patients with severe liver and kidney dysfunction; 3. Patients with bronchospasm; 4. Asthma patients; 5. Patients with active peptic ulcer and bleeding; 6. Patients with severe heart failure; 7. Creatinine clearance rate < 60ml / grade.

Design outcomes

Primary

MeasureTime frame
VAS of pain;PCA dose;

Secondary

MeasureTime frame
ODI score;Down time;Hospitalization time;operative bleeding;surgical time;adverse events;

Countries

China

Contacts

Public ContactYunsheng Ou

The First Affiliated Hospital of Chongqing Medical University

1106642066@qq.com+86 18696669699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 16, 2026